Navigation Links
US FDA Grants Pediatric Exclusivity for UCB's Keppra(R)
Date:6/6/2008

43.1% of levetiracetam-treated patients experiencing at least a 50% reduction in seizure frequency during the evaluation period (five days) compared with 19.6% of placebo-treated patients (p=0.013). Levetiracetam was generally well-tolerated in this pediatric population. The most commonly reported adverse events that occurred more frequently in the treatment group were somnolence (13.3% vs. 1.8% for placebo) and irritability (11.7% vs. 0 for placebo). The incidence of other adverse events was similar in both groups.

In October 2007, UCB announced that it had reached an agreement to settle pending patent infringement lawsuits in the US. Under the terms of the settlement agreement with Mylan, and subject to its receiving FDA approval, Mylan will be allowed to sell its generic levetiracetam tablets effective November 1, 2008, in advance of the expiry of UCB's market exclusivity on January 14, 2009.

About Epilepsy: Epilepsy is a chronic neurological disorder affecting 40 million people worldwide including 2.5 million people in the US. It is caused by abnormal, excessive electrical discharges of the nerve cells or neurons in the brain. Epilepsy is characterized by a tendency to have recurrent seizures and defined by two or more unprovoked seizures. There are many different seizure types and epileptic syndromes and effective classification guides treatment and prognosis. Between 70-80% of individuals are successfully treated with one of the more than 20 antiepileptic drugs now available. However, 20-30% of patients have either intractable or uncontrolled seizures or significant adverse side effects secondary to medication highlighting the ongoing need for the development of new antiepileptic drugs.

About Keppra(R) in the US: Keppra(R) (levetiracetam) tablets were first approved by the FDA in 1999 as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. Since 1999, Keppra(R) has received several supplemental indications
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Xceed Molecular Grants Gen-Probe License to Xceeds Flow-Thru Chip(R) Technology for Multiplex Molecular Diagnostics
2. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
3. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
4. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
5. Susan G. Komen for the Cure(R) Announces Largest Grants Slate Ever: $100 Million to Speed Delivery of Breast Cancer Discoveries, Cures
6. European Union, State of Brandenburg, Award Grants to Alcat Europe, GmbH
7. FDA Grants Market Clearance to Aerocrine Inc.s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. United States Patent Office Grants CryoCors Request for Patent Interference
10. Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- Tute ... interpretation, today announced an agreement with Lineagen, ... for Lineagen,s NextStep Dx PLUS.  Lineagen, ... and neurological disorders, currently offers FirstStep Dx ... testing service used by healthcare providers as ...
(Date:7/10/2014)... THOUSAND OAKS, Calif., July 10, 2014   Ceres, ... biotechnology and seed company, announced today financial results for ... an update on its business. Ceres reported ... progress in product performance this growing season in Brazil, ... that affected the company,s sorghum evaluation areas for part ...
(Date:7/10/2014)... may help in the fight against terrorism with the ... of explosives with the use of light and special ... and Actuators B: Chemical , the researchers describe a ... concentrations as low as 6.3 ppm (parts per million). ... minutes. , "Traditionally explosives detection has involved looking for ...
(Date:7/10/2014)... A new study published today in the journal ... has found that time of day and sleep deprivation ... could be crucial when looking at the best time ... and heart disease, and for administering medicines effectively. , ... of Cancer Research, London, investigated the links between sleep ...
Breaking Biology Technology:Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Detecting trace amounts of explosives with light 2Time of day crucial to accurately test for diseases, new research finds 2
... CRANBURY, N.J., March 11 Amicus Therapeutics (Nasdaq: ... and Chief Executive Officer John F. Crowley will be ... Healthcare Conference. Mr. Crowley,s presentation is scheduled to ... Time.Individuals can listen to a live webcast of the ...
... CITY, March 11 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... on endocrinology and oncology, today reported financial and operating results for ... 2008 Highlights, - February, ... a Phase 2 trial in advanced, ...
... Wednesday, March 11, 2009 at 4:30 p.m. Eastern TimeBOTHELL, ... Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI ... 2008 financial results, reviewed the Company,s highlights and provided ... active year from an execution standpoint as we took ...
Cached Biology Technology:AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 2AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 3AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 4AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 5AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 6AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 7AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 8AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 9AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 10OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 2OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 3OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 4OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 5OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 6OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 7OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 8OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 9OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 10OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 11OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 12
(Date:7/10/2014)... of overfishing in the English Channel has resulted in ... and left fishermen ,scraping the barrel, for increasing amounts ... cod, haddock and many other species at the head ... many removed from the area completely., These are some ... biologists at Plymouth University, in association with international non-profit ...
(Date:7/10/2014)... even if you are a big, bad sea scorpion. ... shallow waters for any prey in sight. The next, ... scientists, you,re reduced to trolling for weaker, soft-bodied animals ... lot of the giant pterygotid eurypterid, the largest arthropod ... published in the journal Biology Letters , dramatically ...
(Date:7/10/2014)... Endomedix, a start-up company housed at NJIT,s business incubator, ... spray-on gel that surgeons will use to staunch bleeding ... onto a surgical site, and the natural bio-polymer solutions ... the patient within 30 seconds. , The gel ... It will translate into less time for the patient,s ...
Breaking Biology News(10 mins):Overfishing in the English Channel leaves fisherman scraping the bottom of the barrel 2Overfishing in the English Channel leaves fisherman scraping the bottom of the barrel 3Extinct sea scorpion gets a Yale eye exam, with surprising results 2A start-up at NJIT develops bleeding-control gel for brain surgery 2
... effect of cocaine on mice by genetically manipulating a ... , While the researchers aren't suggesting that these genetic ... light the key protein that controls cocaine's effects in ... achieve the same results and therefore help addicts overcome ...
... plant species are not only more productive, they are ... extremes, pests and disease over long periods of time. ... of Nature, are the culmination of 12 years of ... at the University of Minnesota, to explore the value ...
... the genes in the fruitfly genome, Johns Hopkins scientists have ... and simultaneously captured a global view of all the genes ... The study, to be published April 3 in Developmental Cell, ... cells that move similarly to spread beyond an original tumor, ...
Cached Biology News:Genetically altered mice no longer like cocaine 2Genetically altered mice no longer like cocaine 3Biodiversity key to sustainable biofuel according to University of Minn. researcher's findings 2Researchers identify genes in fruitflies that may shed light on human cancer spread 2
Chicken polyclonal to YebU ( Abpromise for all tested applications). Antigen: Full length YebU (Escherichia coli)...
Request Info...
Human Cell Line Slides...
... Detection System combines the indirect labeling ... and Signets unique formulation of ultra ... reliablility. Signet reagents will achieve excellent ... automated protocols. ,Signets USA Detection reagents ...
Biology Products: